Lowest dose of progesterone for HRT, and the lowest estrogen doses that still work

What is the lowest dose of progesterone for HRT?

Most women on HRT take micronized progesterone. It is the same hormone your body makes, sold as Prometrium and as a generic.

Two schedules sit at the bottom of the usual range. The cyclic one is 200 mg at bedtime for 12 days of each 28-day cycle. That is the schedule printed on the Prometrium label.

The continuous one is 100 mg every night, with no break. It is the progesterone dose in Bijuva, an FDA-approved capsule that holds estradiol and progesterone together.

The Prometrium label lists only the cyclic schedule. Taking 100 mg nightly alongside a separate estrogen is common practice, and Bijuva is the approved product built on that dose.

Don't compare the milligrams of synthetic progestins with micronized progesterone. A 1.5 mg dose of one is not weaker than 100 mg of the other. Each is a different molecule, tested at its own dose.

Why progesterone can't go lower than the estrogen it protects

Progesterone has one job in HRT. It keeps estrogen from overgrowing the lining of your uterus, which is called the endometrium.

The Menopause Society says the dose and the length of progestogen use both matter for that protection. A progestogen is any hormone that acts like progesterone, natural or synthetic.

Every approved progesterone dose was tested next to a specific estrogen dose. Bijuva's 100 mg was studied with 0.5 mg or 1 mg of oral estradiol.

In that year-long trial, endometrial hyperplasia, an overgrowth of the lining, appeared in about 1 woman in 300 on either strength. None of the 92 women on placebo had it.

The same trial also tested 50 mg doses of progesterone. Those lower doses were never approved. So the progesterone dose that counts is the one tested with your estrogen dose.

• No uterus, no progestogen. After a hysterectomy, estrogen is usually taken alone, because there is no lining to protect.
• Low-dose vaginal estrogen usually needs none. The Menopause Society says a progestogen is generally not needed at the recommended low vaginal doses. It adds that data on the lining beyond one year are lacking.
• A hormonal IUD is an off-label option. The Menopause Society notes that a levonorgestrel IUD can protect the lining off-label. Off-label means the FDA has not approved it for that use.
• One pill skips the progestogen. Duavee pairs conjugated estrogens with bazedoxifene, a drug that protects the lining without a progestogen.

Spotting is common in the first months of a continuous plan. The Menopause Society says bleeding that starts more than six months in should be checked, so tell your prescriber if it happens.

The lowest dose HRT patch, gel, pill and vaginal estrogen

Estrogen is the hormone that calms hot flashes. Each form has its own smallest FDA-approved strength, and some of those strengths are approved for only one use.

Gel and spray numbers are the amount you put on your skin. A patch number is what the patch releases each day. That is why a gel dose looks so much bigger than a patch dose.

A patch and a pill aren't a milligram-for-milligram swap either, because a pill passes through your liver first. Our HRT dosage guide gives the full range for each brand. For how a patch delivers its dose, see hormone patches for menopause.

Is low-dose HRT enough to stop hot flashes?

For many women it is, though relief can take longer to arrive. Several trials compared low doses against a placebo.

In the MsFLASH trial, 0.5 mg of oral estradiol a day cut daily hot flashes by about 53% over eight weeks. Placebo cut them by about 29%.

Bijuva's main trial enrolled women with about 72 moderate to severe hot flashes a week. After 12 weeks, the low strength removed about 54 of them a week. Placebo removed about 40.

The HOPE trial tested lower doses of conjugated estrogens with a progestin. Conjugated estrogens are the mix of estrogens in Premarin, and a progestin is a synthetic progestogen. They relieved hot flashes as well as the standard dose. Taken alone, though, the standard estrogen dose beat the lower ones.

Patience matters here. The Menopause Society notes that lower doses may take 6 to 8 weeks to bring enough relief.

Why "lowest dose, shortest time" is no longer the rule

For years, the motto was the lowest dose for the shortest time. The Menopause Society's 2022 position statement replaced it with the "appropriate dose, duration, regimen, and route" for each woman's goals.

The statement still calls for "the most appropriate, often lowest, effective dose." In other words, low is often right, but relief is the target.

The same statement says Menostar's 0.014 mg patch appears to ease hot flashes. The FDA has approved it only for bone, though.

Lowest dose of estrogen for osteoporosis prevention

Estrogen slows the bone loss that speeds up after menopause. The Menopause Society says the effect on bone density depends on the dose.

The smallest approved option is Menostar, a weekly 0.014 mg patch. Its only FDA approval is to prevent postmenopausal osteoporosis.

In the ULTRA trial, 417 women aged 60 to 80 wore Menostar or a placebo patch for two years. Spine density rose 2.6% on the patch and 0.6% on placebo.

At the hip, density rose 0.4% on the patch. It fell 0.8% on placebo.

The HOPE bone study followed women aged 40 to 65 early in menopause. Every dose, down to 0.3 mg of conjugated estrogens, raised spine and hip density, while the placebo groups lost bone.

The labels mirror this. Premarin starts bone prevention at 0.3 mg, and Climara and Minivelle start it at the 0.025 mg patch.

The oral estradiol label is blunt about pills. It says the lowest effective dose for bone "has not been determined."

Estrogen has a limit here. The Menopause Society says HRT prevents bone loss, but it has no FDA approval to treat osteoporosis you already have.

Labels also ask prescribers to consider non-estrogen bone drugs carefully when bone is the main reason. Even on Menostar, the label says a woman with a uterus should consider adding a progestogen.

Is low-dose estrogen actually safer?

Partly. Dose and route do seem to matter, but most of that evidence comes from observational studies, not trials that compare doses head to head.

Blood clots in the veins show the clearest pattern. In the French ESTHER study, oral estrogen came with about four times the odds of a clot, compared with women not taking HRT.

Estrogen through the skin, by patch or gel, showed no added risk in the same study.

A 2019 UK study in the BMJ found the same split. Oral HRT carried 58% higher odds of a clot than no HRT. Transdermal HRT showed no link.

The Menopause Society adds that lower oral doses may carry less clot risk than higher ones, though comparative trials are lacking. From observational data, lower doses of pills or patches may also carry less stroke risk.

Lower is not the same as protective. HRT is not approved to protect your heart, at any dose. For the everyday effects, see our guide to HRT side effects.

What the FDA changed in February 2026

On February 12, 2026, the FDA approved new labels for a first group of six HRT products. The boxed warning, the FDA's strongest label alert, lost its lines on heart disease, breast cancer and probable dementia.

The six were Prometrium, Bijuva, Divigel, Estring, Cenestin and Enjuvia.

The endometrial cancer warning stays boxed on systemic estrogen-alone products. It covers taking estrogen without a progestogen when you have a uterus.

The FDA said 29 companies had sent in revised labels, so other products follow in batches. In early October 2026, the FDA label database still showed the older boxed warning on Climara and Premarin.

Who low dose HRT suits, and who it doesn't

• Women under 60, or within 10 years of menopause. The Menopause Society calls the benefit-risk balance favorable for this group when there are no reasons to avoid HRT. A low dose is a common place to start.
• Women starting after 60, or more than 10 years after menopause. The Menopause Society says the balance is less favorable here, because the absolute risks of heart disease, stroke, clots and dementia are higher. Observational data suggest lower doses and skin routes carry less clot and stroke risk.
• Early perimenopause. Your own hormones still rise and fall from month to month. A dose that feels right in one month may feel off in the next. HRT is also not birth control. See birth control in perimenopause.
• Early menopause or primary ovarian insufficiency. Primary ovarian insufficiency means the ovaries stop working before age 40. These women usually need full replacement doses, and ACOG lists 100 micrograms a day by patch. The Menopause Society agrees that younger women may need higher doses. For pregnancy prevention, ACOG notes that combined hormonal birth control works more reliably than HRT.

Our guide to hormone therapy in perimenopause covers how HRT fits the years before your last period.

Vaginal low-dose estrogen: does it count as HRT?

It is estrogen therapy, but it works differently. It treats dryness, burning and painful sex, a group of symptoms called genitourinary syndrome of menopause.

The Menopause Society says low-dose vaginal estrogen has minimal absorption into the blood. It prefers these products over whole-body HRT when vaginal symptoms are the only problem.

That low absorption is also why vaginal estrogen is not a hot flash treatment.

Estring was one of the first six products whose boxed warning came off in February 2026. If you prefer a cream, our page on estradiol cream cost compares prices.

Starting low and moving up

Several labels build in a low start. Climara begins at 0.025 mg for hot flashes, Premarin at 0.3 mg, and Bijuva at its lower strength.

Each then says to adjust based on how you respond. Patches come in five or six strengths, so a dose can move up in small steps.

Bijuva's label also asks for a try at tapering or stopping every 3 to 6 months. The full brand-by-brand ladder is in our HRT dosage guide.

Can you go below the lowest manufactured dose?

Not with an FDA-approved product, beyond the strengths listed above.

Cutting a patch is the idea that comes up most. The US estradiol patch labels we checked give no directions for cutting. The labels give no dose for a cut piece.

Some clinics offer compounded micro-doses instead. A compounding pharmacy mixes these to order, and they are not FDA-approved.

The Menopause Society finds "insufficient evidence to support overall clinical use" of compounded bioidentical hormones for menopause symptoms. It adds that patient preference alone should not justify them.

There is little or no good data on how much hormone a compounded product puts into your blood. So there is no way to know that a custom low dose protects your uterine lining. Our page on compounded HRT explains how these products are sold.